Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Chief Financial Officer | October 01, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date October 01, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 111,882 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Disposition to issuer · Disposed 48,081 · Balance 111,882 F1: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 7, 2026 20:11 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Disposition to issuerCommon Shares | 48,081 | $5.00 | $240,405.00 |
DisclosureSEC source: 0001447028-26-000060 · wk-form4_1791403899.xml · nonDerivative · entry 1 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,882 F1 · shares: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,475 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001447028-26-000052 · wk-form4_1790209910.xml · derivative · entry 5 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,925 Underlying: Common Shares · 27,475 shares Expires 2036-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 188,400 shares, vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 2, 2026 grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionStock Option (Right to Buy) · Derivative | 265,625 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001447028-26-000052 · wk-form4_1790209910.xml · derivative · entry 4 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 484,375 Underlying: Common Shares · 265,625 shares Expires 2035-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 750,000 shares, vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the March 31, 2025 grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Tax withholdingCommon Shares | 206,637 | $5.07 | $1,047,649.59 |
DisclosureSEC source: 0001447028-26-000052 · wk-form4_1790209910.xml · nonDerivative · entry 3 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,963 F1 · kind: The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 206,637 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionCommon Shares | 27,475 | $4.39 | $120,615.25 |
DisclosureSEC source: 0001447028-26-000052 · wk-form4_1790209910.xml · nonDerivative · entry 2 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionCommon Shares | 265,625 | $3.49 | $927,031.25 |
DisclosureSEC source: 0001447028-26-000052 · wk-form4_1790209910.xml · nonDerivative · entry 1 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 20:21 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 188,400 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001447028-26-000009 · wk-form4_1770081692.xml · derivative · entry 2 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,400 Underlying: Common Shares · 188,400 shares Expires 2036-02-02 F2 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 20:21 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantCommon Shares | 73,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001447028-26-000009 · wk-form4_1770081692.xml · nonDerivative · entry 1 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,500 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document |
| March 31, 2025 Filed Mar 31, 2025 16:24 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001447028-25-000088 · wk-form4_1743452635.xml · derivative · entry 1 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Shares · 750,000 shares Expires 2035-03-31 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 17:47 UTC Amendment | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001447028-25-000090 · wk-form4a_1743544061.xml · derivative · entry 1 Nguyen Tuan · CIK 0002063445 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Shares · 750,000 shares Expires 2035-03-31 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.